Core Viewpoint - ORIC Pharmaceuticals, Inc. will report combination dose optimization data from the Phase 1b trial of rinzimetostat (ORIC-944) for metastatic castration resistant prostate cancer on March 31, 2026 [1] Group 1: Company Overview - ORIC Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing treatments that address mechanisms of therapeutic resistance in cancer [3] - The company's product candidates include rinzimetostat (ORIC-944), an allosteric inhibitor for prostate cancer, and enozertinib (ORIC-114), a brain-penetrant inhibitor for non-small cell lung cancer (NSCLC) [3] - ORIC has offices located in South San Francisco and San Diego, California [3] Group 2: Conference Call Details - A conference call and webcast will take place on March 31, 2026, at 4:30 pm ET to discuss the trial data [1] - Participants can pre-register online to join the conference call and will receive a unique passcode for entry [2] - The webcast will be available for replay for 90 days following the presentation [2]